HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Adenylosuccinic Acid: An Orphan Drug with Untapped Potential.

Abstract
Adenylosuccinic acid (ASA) is an orphan drug that was once investigated for clinical application in Duchenne muscular dystrophy (DMD). Endogenous ASA participates in purine recycling and energy homeostasis but might also be crucial for averting inflammation and other forms of cellular stress during intense energy demand and maintaining tissue biomass and glucose disposal. This article documents the known biological functions of ASA and explores its potential application for the treatment of neuromuscular and other chronic diseases.
AuthorsEmma Rybalka, Stephanie Kourakis, Charles A Bonsett, Behzad Moghadaszadeh, Alan H Beggs, Cara A Timpani
JournalPharmaceuticals (Basel, Switzerland) (Pharmaceuticals (Basel)) Vol. 16 Issue 6 (May 31 2023) ISSN: 1424-8247 [Print] Switzerland
PMID37375769 (Publication Type: Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: